| Open | 1.08 |
| Previous Close | 1.08 |
| Volume | 110.2 Thou. |
| Average Volume | 220 Thou. |
| Day's Range | 1.05 โ 1.1 |
| 52 Week Range | 0.87-3.07 |
| Market Cap | 31.99 Mil. |
| Moving Average (50) | 1.1705 |
| Moving Average (200) | 1.2087 |
| Earnings per Share (EPS) | -1.51 |
| Price/Earnings (PE) | -0.7 |
| Shares Outstanding | 30.18 Mil. |
| Earnings Date | Aug 14, 2025 |
| Beta | -0.082 |
| Last Dividend | 0 |
ANTX Latest News
|
|
|
|
|
|
|
|
|
|
ANTX Business Model
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| About AN2 Therapeutics | |
| Industry | Biotechnology |
| Sector | Healthcare |
| Number of Employees | 22 |
| Website & Executive | |
| Website | https://www.an2therapeutics.com |
| CEO (Chief Executive Officer) | Eric E. Easom |
| IPO date | 2022-03-25 |
| Contact | |
| Country | US |
| Address | 1800 El Camino Real |
| City | Menlo Park |
| State | CA |
| Phone | 650-331-9090 |
| Zip Code | 94027 |
| Other Identifiers | |
| CIK | 0001880438 |
| ISIN | US0373261058 |
| CUSIP | 037326105 |
